Corcept Therapeutics Incorporated (NASDAQ:CORT) was upgraded by research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday.

Several other brokerages also recently commented on CORT. Zacks Investment Research raised Corcept Therapeutics from a “hold” rating to a “strong-buy” rating and set a $14.00 price objective for the company in a research note on Wednesday, July 19th. Ladenburg Thalmann Financial Services set a $20.00 price objective on Corcept Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, July 18th. TheStreet raised Corcept Therapeutics from a “c+” rating to a “b” rating in a research note on Monday, May 22nd. Finally, Piper Jaffray Companies set a $18.00 price objective on Corcept Therapeutics and gave the stock a “buy” rating in a research note on Monday, May 15th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $14.20.

Corcept Therapeutics (CORT) traded down 0.48% on Tuesday, reaching $12.47. The company’s stock had a trading volume of 428,740 shares. The company has a market cap of $1.41 billion, a P/E ratio of 114.40 and a beta of 2.05. The firm’s 50-day moving average price is $11.92 and its 200 day moving average price is $10.16. Corcept Therapeutics has a 52-week low of $5.24 and a 52-week high of $13.25.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Monday, May 1st. The biotechnology company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.03 by $0.01. The firm had revenue of $27.60 million during the quarter, compared to the consensus estimate of $25.53 million. Corcept Therapeutics had a return on equity of 33.97% and a net margin of 13.51%. The firm’s revenue for the quarter was up 71.9% on a year-over-year basis. Equities analysts anticipate that Corcept Therapeutics will post $0.26 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.dailypolitical.com/2017/07/25/corcept-therapeutics-incorporated-nasdaqcort-raised-to-strong-buy-at-bidaskclub.html.

In other news, Director David L. Mahoney sold 6,994 shares of the company’s stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $12.50, for a total value of $87,425.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Gary Charles Robb bought 5,600 shares of Corcept Therapeutics stock in a transaction dated Thursday, May 4th. The stock was acquired at an average cost of $9.75 per share, with a total value of $54,600.00. Following the completion of the acquisition, the chief financial officer now owns 6,858 shares of the company’s stock, valued at $66,865.50. The disclosure for this purchase can be found here. Over the last three months, insiders sold 42,601 shares of company stock valued at $532,513. Company insiders own 19.20% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in CORT. Hillsdale Investment Management Inc. acquired a new position in Corcept Therapeutics during the first quarter valued at about $1,132,000. Trexquant Investment LP acquired a new position in Corcept Therapeutics during the first quarter valued at about $202,000. UBS Asset Management Americas Inc. raised its position in Corcept Therapeutics by 178.6% in the first quarter. UBS Asset Management Americas Inc. now owns 46,217 shares of the biotechnology company’s stock valued at $507,000 after buying an additional 29,629 shares in the last quarter. Bank of New York Mellon Corp raised its position in Corcept Therapeutics by 96.3% in the first quarter. Bank of New York Mellon Corp now owns 884,647 shares of the biotechnology company’s stock valued at $9,696,000 after buying an additional 434,080 shares in the last quarter. Finally, Chicago Equity Partners LLC raised its position in Corcept Therapeutics by 5.2% in the first quarter. Chicago Equity Partners LLC now owns 54,435 shares of the biotechnology company’s stock valued at $597,000 after buying an additional 2,680 shares in the last quarter. 53.49% of the stock is owned by institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.